RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 167 filers reported holding RIGEL PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $25,152 | -3.9% | 23,289 | +14.8% | 0.00% | 0.0% |
| Q2 2023 | $26,173 | -4.7% | 20,289 | -2.4% | 0.00% | -50.0% |
| Q1 2023 | $27,452 | -19.7% | 20,797 | -8.8% | 0.00% | 0.0% |
| Q4 2022 | $34,200 | +80.0% | 22,800 | +39.9% | 0.00% | +100.0% |
| Q3 2022 | $19,000 | -20.8% | 16,300 | -23.5% | 0.00% | -50.0% |
| Q2 2022 | $24,000 | -62.5% | 21,300 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $64,000 | +14.3% | 21,300 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $56,000 | -30.9% | 21,300 | -34.1% | 0.00% | -33.3% |
| Q3 2021 | $81,000 | -15.6% | 32,300 | -26.3% | 0.01% | -14.3% |
| Q2 2021 | $96,000 | +62.7% | 43,800 | +153.2% | 0.01% | +40.0% |
| Q1 2021 | $59,000 | -16.9% | 17,300 | -14.8% | 0.01% | -28.6% |
| Q4 2020 | $71,000 | +36.5% | 20,300 | -7.2% | 0.01% | +16.7% |
| Q3 2020 | $52,000 | – | 21,870 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
| Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
| ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
| GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
| NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
| Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
| XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |